RTP Mobile Logo
Consensus or Controversy: Clinical Investigators Provide Their Perspectives on Practical Issues and Research Questions in the Management of Non-Small Cell Lung Cancer
Released August 2012

Audio proceedings of a live educational activity held adjunct to the 2012 ASCO Annual Meeting on controversial issues in the management of lung cancer featuring the perspectives of Drs Corey J Langer, Thomas J Lynch Jr, Lecia V Sequist, Mark A Socinski and Jean-Charles Soria. (Audio Content)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE

    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).

    OVERVIEW OF ACTIVITY

    Lung cancer is a devastating disease with a broad-reaching impact on public health, accounting for 15% of all new cancer cases in the United States and the most cancer-related deaths among both men and women. Development of new therapeutic strategies beyond cytotoxic chemotherapy has been the focus of extensive recent research and has led to an explosion in lung cancer genetic and biologic knowledge. The advent of these next-generation targeted treatments presents new promise of both efficacy and enhanced safety for patients with lung cancer but also challenges practicing oncologists to appropriately select individuals who may benefit from these agents and to determine how to integrate such therapies, as they become available, into standard lung cancer treatment algorithms. Several consensus- and evidence-based treatment guidelines are available and aim to assist clinicians with making lung cancer management decisions in the face of this dynamic clinical environment, but despite the existence of these tools, many areas of controversy persist within academic and community settings. This program uses a review of recent relevant publications and other relevant presentations, ongoing clinical trials and Q&A to assist medical oncologists, hematology-oncology fellows and other healthcare providers with the formulation of up-to-date clinical management strategies, including referral of appropriate patients to ongoing pivotal clinical trials.

    LEARNING OBJECTIVES

    • Develop an evidence-based strategy for the initial diagnosis and treatment of localized NSCLC, exploring the role of neoadjuvant and adjuvant systemic therapy.
    • Use biomarkers, clinical characteristics and tumor histology to select individualized front-line and subsequent treatment approaches for patients with metastatic NSCLC.
    • Compare and contrast the benefits and risks of combination chemobiologic, doublet and single-agent chemotherapy regimens when developing treatment plans for patients with advanced NSCLC.
    • Recognize the effect of NSCLC tumor-specific mutations on relative response or resistance to treatment with EGFR TKIs, monoclonal antibodies and other emerging molecular-targeted agents.
    • Identify patients with metastatic NSCLC who may experience clinical benefit from the addition of continuation or switch maintenance biologic therapy and/or chemotherapy.
    • Recall the design of ongoing clinical trials evaluating novel investigational agents in NSCLC, and counsel appropriately selected patients about availability and participation.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT

    Research To Practice designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    HOW TO USE THIS CME ACTIVITY

    This CME activity contains an audio component. To receive credit, the participant should review the CME information, listen to the audio MP3s, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located on our website at ResearchToPractice.com/ASCOLung12/CME.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Corey J Langer, MD
    Director of Thoracic Oncology, Abramson Cancer Center
    Professor of Medicine, University of Pennsylvania
    Vice Chair, Radiation Therapy Oncology Group
    Philadelphia, Pennsylvania

    Advisory Committee and Consulting Agreements: Allos Therapeutics, ARIAD Pharmaceuticals Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, OSI Oncology, Pfizer Inc; Data and Safety Monitoring Committee: Amgen Inc.

    Thomas J Lynch Jr, MD
    Jonathan and Richard Sackler Professor of Internal Medicine
    Director, Yale Cancer Center
    Physician-in-Chief
    Smilow Cancer Hospital at Yale New Haven
    New Haven, Connecticut

    Advisory Committee and Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Merck and Company Inc, SuperGen Inc; Board of Directors and Stock Ownership: Infinity Pharmaceuticals Inc.

    Lecia V Sequist, MD, MPH
    Assistant Professor of Medicine, Harvard Medical School
    Center for Thoracic Cancers
    Massachusetts General Hospital Cancer Center
    Boston, Massachusetts

    Advisory Committee: Daiichi Sankyo Inc, GlaxoSmithKline; Paid Research: ArQule Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Daiichi Sankyo Inc, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Merrimack Pharmaceuticals, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi.

    Mark A Socinski, MD
    Professor of Medicine and Thoracic Surgery
    Director, Lung Cancer Section
    Division of Hematology/Oncology
    Co-Director, UPMC Lung Cancer Center of Excellence
    Co-Director, Lung and Thoracic Malignancies Program
    University of Pittsburgh, UPMC Cancer Pavilion
    Pittsburgh, Pennsylvania

    Paid Research: Celgene Corporation, Genentech BioOncology, Lilly USA LLC, Pfizer Inc, Synta Pharmaceuticals Corp; Speakers Bureau: Genentech BioOncology, Lilly USA LLC.

    Jean-Charles Soria, MD, PhD
    Full Professor, Paris University XI
    Division of Cancer Medicine
    Institut Gustave Roussy
    Villejuif, France

    Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, EMD Serono Inc, Genentech BioOncology, Lilly USA LLC, Pfizer Inc, Roche Laboratories Inc, Sanofi; Paid Research: Lilly USA LLC, Roche Laboratories Inc.

    MODERATOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Lilly USA LLC.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: July 2012
    Expiration date: July 2013

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

    This presentation was selected by the American Society of Clinical Oncology® as an independent educational activity held adjunct to the ASCO Annual Meeting. This presentation is not sponsored or endorsed by ASCO.

Acknowledge and close

Listen to audio:
Consensus or Controversy: Clinical Investigators Provide Their Perspectives on Practical Issues and Research Questions in the Management of Non-Small Cell Lung Cancer
Released August 2012

Audio proceedings of a live educational activity held adjunct to the 2012 ASCO Annual Meeting on controversial issues in the management of lung cancer featuring the perspectives of Drs Corey J Langer, Thomas J Lynch Jr, Lecia V Sequist, Mark A Socinski and Jean-Charles Soria. (Audio Content)

Read print: